---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-040779"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T14:13:30.650424+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics FY2024 net loss $14.9M; cash $38.3M; pipeline updates for ALS and FTD trials

## Summary
- Net loss $14.9M in 2024 vs $8.0M in 2023; R&D expenses $11.9M (up from $5.5M).
- Cash and equivalents $38.3M as of Dec 31, 2024; raised $10M private placement and $5M from ADDF.
- Received $3.85M from Dr. Reddy's for COYA-302 ALS Phase 2; eligible for additional $8.4M milestone.
- Plan to submit nonclinical data to FDA in Q2 2025 for COYA-302 ALS Phase 2b trial initiation.
- Expect to file IND for COYA-302 Phase 2b in FTD in 2H 2025; top-line data from investigator trial also in 2H 2025.

## SEC filing metadata
- accession: 0000950170-25-040779
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000095017025040779/0000950170-25-040779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000095017025040779/coya-20250318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-040779
- JSON: https://secwatch.observer/filing/0000950170-25-040779.json
- Plain text: https://secwatch.observer/filing/0000950170-25-040779.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.